—
C+
C+ The full Closelook — membership. Open the C+ overview

Immunovant Inc (IMVT) — Quality & forensics

As of 2026-09-24 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.

The Closelook module scores

31 /100 composite · 7 modules · general weight set

Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.

Financial forensics — the academic screens

37.45 Altman Z-Score

Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.

2/7 Piotroski F-Score

Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.

Continue: the IMVT chart & overview · the earnings record

FAQ · from the current data · as of 2026-09-24

Quick answers

What is Immunovant Inc's Closelook quality reading?

The composite reads 31/100 across 7 modules, as of 2026-09-24: valuation 3, quality 1, growth 24, balance sheet 96, cash quality 44, capital allocation 7, momentum 58. Closelook scores are research diary readings, not ratings or investment advice.

What is Immunovant Inc's Altman Z-Score?

37.45, which sits in the safe zone (above 2.99) as of 2026-09-24. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.

What is Immunovant Inc's Piotroski F-Score?

2 of 7, as of 2026-09-24. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.